drugset / Trial / NCT00476554
A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell Lymphoma
RandomizedParallel-groupOpen-labelTreatment
Summary
This is an open label, randomized phase II study designed to evaluate the tolerability and response rate of high-dose and low-dose regimens in patients with advanced cutaneous T-cell lymphoma (CTCL).
Timeline
- Start
- 2007-04
- Primary completion
- 2012-03-01
- Completion
- 2012-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | sapacitabine | Small molecule | 100 mg | Oral |
| Subject | sapacitabine | Small molecule | 200 mg | Oral |